A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with type 2 diabetes mellitus, treated with insulin glargine 300 U/mL (insulin glargine U300 before, during and after the period of Ramadan - ORION
Latest Information Update: 09 Mar 2022
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms ORION
- Sponsors Sanofi
Most Recent Events
- 03 Mar 2022 Results of subgroup analysis evaluating the safety and effectiveness of insulin glargine 300 U/mL in people with type 2 diabetes mellitus in the Gulf region who fast during Ramadan, published in the Diabetes Therapy
- 26 Sep 2019 New trial record